European Journal of Cancer
Volume 42, Issue 15 , Pages 2433-2453 , October 2006

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours

  • M.S. Aapro

      Affiliations

    • Multidisciplinary Oncology Institute, Clinique de Genolier, 1, route du Muids, 1272 Genolier, Switzerland
    • Corresponding Author InformationCorresponding author: Tel.: +41 22 366 9106; fax: +41 22 366 9131.
    • Member of the EORTC Board and Chair of the EORTC Task Force Elderly.
    • ,
  • D.A. Cameron

      Affiliations

    • Department of Oncology, University of Edinburgh and Western General Hospital, Edinburgh, Scotland
    • Representative of the EORTC Breast Cancer Group.
    • ,
  • R. Pettengell

      Affiliations

    • Department of Haematology, St George’s Hospital, University of London, London, UK
    • Member of the EORTC and Lymphoma Expert.
    • ,
  • J. Bohlius

      Affiliations

    • Department I of Internal Medicine, University of Cologne, Cologne, Germany
    • Methodology Expert.
    • ,
  • J. Crawford

      Affiliations

    • Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, NC, USA
    • Member of MASCC (Multinational Association for Supportive Care in Cancer) and US Expert.
    • ,
  • M. Ellis

      Affiliations

    • UAE University, Faculty of Medicine and Health Sciences, Abu Dhabi, United Arab Emirates
    • Member of the EORTC Infectious Diseases Group.
    • ,
  • N. Kearney

      Affiliations

    • Cancer Care Research Centre, Department of Nursing and Midwifery, University of Stirling, Stirling, UK
    • Nursing Expert, mandated by EONS (European Oncology Nursing Society).
    • ,
  • G.H. Lyman

      Affiliations

    • James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    • US Expert.
    • ,
  • V.C. Tjan-Heijnen

      Affiliations

    • Radboud University Nijmegen, Department of Medical Oncology, Nijmegen, The Netherlands
    • Representative of the EORTC Lung Cancer Group.
    • ,
  • J. Walewski

      Affiliations

    • The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warszawa, Poland
    • Representative of the EORTC Lymphoma Group.
    • ,
  • D.C. Weber

      Affiliations

    • Department of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland
    • Representative of the EORTC Radiation Therapy Group.
    • ,
  • C. Zielinski

      Affiliations

    • Clinical Division of Oncology, Department of Medicine I, University Hospital, Central European Cooperative Oncology Group, Vienna, Austria
    • Breast Cancer Expert and Representative of CECOG (Central European Cooperative Oncology Group).
    • ,
  • European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party

Received 16 May 2006 ,Accepted 16 May 2006.

References 

  1. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21:4524–4531
  2. Lyman GH, Morrison VA, Dale DC, et al. OPPS Working Group ANC Study Group Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma. 2003;44:2069–2076
  3. Wolff DA, Crawford J, Dale DC, Poniewierski MS, Lyman GH. Risk of neutropenic complications based on a prospective nationwide registry of cancer patients initiating systematic chemotherapy. Proc Am Soc Clin Oncol. 2004;23:547;(abstract 6125)
  4. Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer. 2003;98:2402–2409
  5. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178–1183
  6. Timmer-Bonte JN, de Boo TM, Smit HJ, et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomised phase III study. J Clin Oncol. 2005;23:7974–7984
  7. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328–340
  8. Meza L, Baselga J, Holmes FA, Liang B, Breddy J for the Pegfilgrastim Study Group. Incidence of febrile neutropenia (FN) is directly related to duration of severe neutropenia (DSN) after myelosuppressive chemotherapy. Proc Am Soc Clin Oncol. 2002;21:255b;(abstract 2840)
  9. Padilla G, Ropka ME. Quality of life and chemotherapy-induced neutropenia. Cancer Nurs. 2005;28:167–171
  10. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of haematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. 2000;18:3558–3585
  11. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–751
  12. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90:1205–1211
  13. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990;8:963–977
  14. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332:901–906
  15. Lepage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non-Hodgkin’s lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d’Etude des Lymphomes de l’Adulte). Ann Oncol. 1993;4:651–656
  16. Chang J. Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer. 2000;36(Suppl. 1):S11–S14
  17. Mayers C, Panzarella T, Tannock IF. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer. 2001;91:2246–2257
  18. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994;330:1253–1259
  19. National Comprehensive Guidelines Network. Myeloid Growth Factors. Available from: http://www.nccn.org. Accessed 7 September 2005.
  20. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100:228–237
  21. Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005;10:427–437
  22. Komrokji RS, Lyman GH. The colony-stimulating factors: use to prevent and treat neutropenia and its complications. Expert Opin Biol Ther. 2004;4:1897–1910
  23. Cullen M, Steven N, Billingham L, et al. Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/− Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;353:988–998
  24. Bucaneve G, Micozzi A, Menichetti F, et al. Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Infection Program Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977–987
  25. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005;142:979–995
  26. van de Wetering MD, de Witte MA, Kremer LC, Offringa M, Scholten RJ, Caron HN. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer. 2005;41:1372–1382
  27. Bonadio M, Morelli G, Mori S, Riccioni R, Papineschi F, Petrini M. Fluoroquinolone resistance in hematopoietic stem cell transplant recipients with infectious complications. Biomed Pharmacother. 2005;59:511–516
  28. Crawford J. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Semin Oncol. 2003;30(4 Suppl. 13):24–30
  29. Green MD, Koelbl H, Baselga J, et al. A randomised double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14:29–35
  30. Holmes FA, Jones SE, O’Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol. 2002;13:903–909
  31. Holmes FA, O’Shaughnessy JA, Vukelja S, et al. Blinded, randomised, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20:727–731
  32. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol. 1988;121–141
  33. Garcia-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst. 2001;93:31–38
  34. Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomised controlled trials. J Clin Oncol. 2005;23:4198–4214
  35. Gregory SA, Trumper L. Chemotherapy dose intensity in non-Hodgkin’s lymphoma: is dose intensity an emerging paradigm for better outcomes?. Ann Oncol. 2005;16:1413–1424
  36. Pfreundschuh M, Trumper L, Kloess M, et al. German High-Grade Non-Hodgkin’s Lymphoma Study Group Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104:634–641
  37. Pfreundschuh M, Trumper L, Kloess M, et al. German High-Grade Non-Hodgkin’s Lymphoma Study Group Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626–633
  38. Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomised Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol. 2000;18:395–404
  39. Steward WP, von Pawel J, Gatzemeier U, et al. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomised study of 300 patients. J Clin Oncol. 1998;16:642–650
  40. Sonneveld P, van Putten W, Holte H, et al. Intensified CHOP with rituximab for intermediate or high-risk non-Hodgkin’s lymphoma: interim analysis of a randomized phase III trial in elderly patients by the Dutch HOVON and Nordic Lymphoma Groups. Blood. 2005;106(11):16;(abstract)
  41. Pfreundschuh M, Kloess M, Schmits R, et al. Six, not eight cycles of bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2005;106(11):13;(abstract)
  42. Repetto L, Biganzoli L, Koehne CH, et al. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer. 2003;39:2264–2272
  43. American Society of Clinical Oncology. ASCO guideline procedures manual available at http://www.asco.org/ac/1,1003,_12-002562-00_18-0026185-00_19-00-00_20-001,00.asp last accessed 20th December 2005.
  44. Millward MJ, Boyer MJ, Lehnert M, et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol. 2003;14:449–454
  45. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol. 1995;13:2688–2699
  46. Fosså S, Kaye SB, Mead GM, et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol. 1998;16:716–724
  47. Tjan-Heijnen VC, Postmus PE, Ardizzoni A, et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol. 2001;12:1359–1368
  48. Ravaud A, Chevreau C, Cany L, et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomised phase III trial. J Clin Oncol. 1998;16:2930–2936
  49. Vellenga E, Uyl-de Groot CA, de Wit R, et al. Randomised placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. J Clin Oncol. 1996;22:619–627
  50. Brooks JM, Klesper DG, Chrischilles EA, et al. Estimating derived demand curves for healthcare treatments: the case of primary G-CSF for non-Hodgkin’s lymphoma patients. Value Health, in press.
  51. Dale DC, Goldschmidt JH, Crawford J, Lyman GH for the ANC Study Group. Reduced relative dose intensity (RDI) in patients with aggressive non-Hodgkin’s lymphoma (NHL). Blood. 2004;104(11):3314;(abstract)
  52. Dale DC, Wolff D, Agboola O, et al. Prospective patient registry for the development of risk models of neutropenic complications including febrile neutropenia (FN). Blood. 2002;100:502b
  53. Lyman GH, Crawford J, Dale DC, Wolff A, Culakova E The ANC Study Group. Predicting the risk of neutropenic complications and reduced dose intensity in patients with early-stage breast cancer (ESBC): results from a prospective nationwide registry. Proc Am Soc Clin Oncol. 2004;24:70;(abstract 776)
  54. Perez EA, Geeraerts L, Suman VJ, et al. A randomised phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer. Ann Oncol. 2002;13:1225–1235
  55. von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol. 2005;23:2676–2685
  56. Alba E, Martin M, Ramos M, et al. Spanish Breast Cancer Research Group Multicenter randomised trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol. 2004;22:2587–2593
  57. Nabholtz JM, Falkson C, Campos D, et al. TAX 306 Study Group Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomised, multicenter, phase III trial. J Clin Oncol. 2003;21:968–975
  58. Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol. 2002;20:3114–3121
  59. Martin M, Lluch A, Seguí MA, et al. Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): an interim safety analysis of the GEICAM 9805 study. Proc Am Soc Clin Oncol. 2004;22:14S;(abstract 620)
  60. von Minckwitz G, Blohmer JU, Löhr A, et al. Primary prophylaxis with 3 weekly pegfilgrastim and ciprofloxacin effectively prevent (febrile) neutropenia and infection during neoadjuvant chemotherapy with docetaxel/doxorubicin/cyclophosphamide (TAC) in breast cancer patients. In: ASCO Annual Meeting, 13–17 May, Orlando, Florida, 2005. p. 8008 (abstract).
  61. Chevallier B, Chollet P, Merrouche Y, et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol. 1995;13:1564–1571
  62. Citron ML, Berry DA, Cirrincione C, et al. Randomised trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21:1431–1439
  63. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. EORTC Final results of a randomised phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol. 2003;21:843–850
  64. Norris B, Pritchard KI, James K, et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol. 2000;18:2385–2394
  65. O’Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20:2812–2823
  66. Fumoleau P, Chauvin F, Namer M, et al. Intensification of adjuvant chemotherapy: 5-year results of a randomised trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes. J Clin Oncol. 2001;19:612–620
  67. Stöger H, Samonigg H, Krainer M, et al. Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor. Eur J Cancer. 1998;34:482–488
  68. Levine MN, Bramwell VH, Pritchard KI, et al. Randomised trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16:2651–2658
  69. Zielinski C, Beslija S, Mrsic-Krmpotic Z, et al. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. J Clin Oncol. 2005;23:1401–1408
  70. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomised trial. J Clin Oncol. 2001;19:602–611
  71. Tannock IF, Boyd NF, DeBoer G, et al. A randomised trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol. 1988;6:1377–1387
  72. Ron IG, Wigler N, Borovik R, et al. CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomised multicenter study. Am J Clin Oncol. 2001;24:323–327
  73. Jassem J, Pienkowski T, Pluzanska A, et al. Central & Eastern Europe and Israel Paclitaxel Breast Cancer Study Group Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III multicenter trial. J Clin Oncol. 2001;19:1707–1715
  74. Papaldo P, Lopez M, Marolla P, et al. Impact of five prophylactic filgrastim schedules on haematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol. 2005;23:6908–6918
  75. Crawford J, Kreisman H, Garewal H, et al. The impact of filgrastim schedule variation on haematopoietic recovery post-chemotherapy. Ann Oncol. 1997;8:1117–1124
  76. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164–170
  77. Ardizzoni A, Manegold C, Debruyne C, et al. Giuseppe Giaccone European organization for research and treatment of cancer (EORTC) lung cancer group European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res. 2003;9:143–150
  78. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer A. 1993;29:319–324
  79. Von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17:658–667
  80. Lorigan P, Woll PJ, O’Brien ME, Ashcroft LF, Sampson MR, Thatcher N. Randomised phase III trial of dose-dense chemotherapy supported by whole-blood haematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst. 2005;97:666–674
  81. Woll PJ, Hodgetts J, Lomax L, Bildet F, Cour-Chabernaud V, Thatcher N. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomised controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol. 1995;13:652–659
  82. Masutani M, Ochi Y, Kadota A, et al. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomised trial, can it improve survival of patients with good prognostic factors?. Oncol Rep. 2000;7:305–310
  83. White SC, Lorigan P, Middleton MR, et al. Randomised phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma. Cancer. 2001;92:601–608
  84. Furuse K, Fukuoka M, Nishiwaki Y, et al. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. J Clin Oncol. 1998;16:2126–2132
  85. Edelman MJ, Chansky K, Gaspar LE, et al. Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713. J Clin Oncol. 2004;22:127–132
  86. Font A, Moyano AJ, Puerto JM, et al. Increasing dose intensity of cisplatin-etoposide in advanced non-small-cell lung carcinoma: a phase III randomised trial of the Spanish Lung Cancer Group. Cancer. 1999;85:855–863
  87. Baldini E, Ardizzoni A, Prochilo T, Cafferata MA, Boni L, Tibaldi C. Gemcitabine, ifosfamide and Navelbine (GIN): a platinum-free combination in advanced non-small-cell lung cancer (NSCLC). Cancer Chemother Pharmacol. 2002;49(Suppl. 1):S25–S28
  88. Schiller JH, Harrington D, Belani CP, et al. Eastern Cooperative Oncology Group Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98
  89. Fossella F, Pereira JR, von Pawel J, et al. Randomised, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21:3016–3024
  90. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomised trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998;16:2459–2465
  91. Kelly K, Crowley J, Bunn PA, et al. Randomised phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210–3218
  92. Stathopoulos GP, Rigatos SK, Dimopoulos MA, et al. Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol. 2003;14:388–394
  93. Kosmidis P, Mylonakis N, Dimopoulos A, et al. Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: a phase III randomised study. Preliminary results. Hellenic Cooperative Oncology Group. Semin Oncol. 2000;27:3–8
  94. Scagliotti GV, De Marinis F, Rinaldi M, et al. Italian Lung Cancer Project Phase III randomised trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002;20:4285–4291
  95. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomised phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999;17:12–18
  96. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71:117–122
  97. Johnson PW, Sweetenham JW, McCallum P, Norton AJ, Rohatiner AZ, Lister TA. E-SHAP: inadequate treatment for poor-prognosis recurrent lymphoma. Ann Oncol. 1993;4:63–67
  98. Ozturk MA, Barista I, Altundag MK, et al. Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin’s lymphoma: results of a single-center study of 32 patients. Modified etoposide, methylprednisolone, cytarabine and cisplatin. Chemotherapy. 2002;48:252–258
  99. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP – an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994;12:1169–1176
  100. Ösby E, Hagberg H, Kvaloy S, et al. Nordic Lymphoma Group CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomised trial. Blood. 2003;101:3840–3848
  101. Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomised controlled trial. Blood. 1992;80:1430–1436
  102. Gisselbrecht C, Haioun C, Lepage E, et al. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin’s lymphoma: factors influencing chemotherapy administration. Groupe d’Etude des Lymphomes de l’Adulte. Leuk Lymphoma. 1997;25:289–300
  103. Martinelli G, Ferrucci PF, Mingrone W, et al. ACOD, a modified CHOP regimen for elderly patients with aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44:801–806
  104. Dimopoulos MA, Fountzilas G, Papageorgiou E, et al. Hellenic Cooperative Oncology Group Primary treatment of low-grade non-Hodgkin’s lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group. Leuk Lymphoma. 2002;43:111–114
  105. Verschraegen CF, Sittisomwong T, Kudelka AP, et al. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol. 2000;18:2733–2739
  106. Omura GA, Brady MF, Look KY, et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. J Clin Oncol. 2004;21:2843–2848
  107. Guppy AE, Nelstrop AE, Foster T, Agarwal R, Seckl MJ, Rustin GJ. A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer. Br J Cancer. 2004;90:810–814
  108. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol. 1996;14:3056–3061
  109. Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol. 1998;16:3345–3352
  110. Gordon AN, Asmar L, Messing MJ, et al. Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2004;94:533–539
  111. du Bois A, Luck HJ, Meier W, et al. Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group A randomised clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320–1329
  112. Papadimitriou CA, Fountzilas G, Aravantinos G, et al. Hellenic Cooperative Oncology Group Study Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study. Gynecol Oncol. 2004;92:152–159
  113. Vaughn DJ, Malkowicz SB, Zoltick B, et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol. 1998;16:255–260
  114. Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomised phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001;19:2638–2646
  115. Miller KD, Loehrer PJ, Gonin R, Einhorn LH. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol. 1997;15:1427–1431
  116. Motzer RJ, Sheinfeld J, Mazumdar M, et al. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. J Clin Oncol. 1995;13:2700–2704
  117. Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine vs. intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 2004;90:1190–1197
  118. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905–914
  119. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041–1047
  120. Mabro M, Louvet C, Andre T, et al. GERCOR Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. Am J Clin Oncol. 2003;26:254–258
  121. Leonard P, Seymour MT, James R, Hochhauser D, Ledermann JA. Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. Br J Cancer. 2002;87:1216–1220
  122. Sorbye H, Glimelius B, Berglund A, et al. Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2004;22:31–38
  123. Maindrault-Goebel F, de Gramont A, Louvet C, et al. Oncology Multidisciplinary Research Group (GERCOR) High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer. 2001;37:1000–1005
  124. Schoemaker NE, Kuppens IE, Moiseyenko V, et al. A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. Br J Cancer. 2004;91:1434–1441
  125. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol. 2003;21:807–814
  126. Shin DM, Khuri FR, Glisson BS, et al. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer. 2001;91:1316–1323
  127. Bui BN, Chevallier B, Chevreau C, et al. Efficacy of lenograstim on haematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol. 1995;13:2629–2636
  128. Rose PG, Blessing JA, Gershenson DM, McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 1999;17:2676–2680
  129. Silvestri F, Fanin R, Velisig M, et al. The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin’s disease. Tumori. 1994;80:453–458
  130. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22:2159–2166
  131. Stathopoulos GP, Veslemes M, Georgatou N, et al. Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomised phase III trial. Ann Oncol. 2004;15:1048–1055
  132. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol. 2002;20:630–637
  133. Capotorto AM, Pavesi L, Pedrazzoli P, et al. Randomised, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma. J Chemother. 2003;15:184–191
  134. Frasci G, Comella P, Carreca I, et al. Southern Italy Cooperative Oncology Group Weekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support does not substantially improve prognosis in extensive disease small-cell lung cancer. A SICOG phase II study. Oncology. 2005;68:223–229
  135. Masutani M, Tsujino I, Fujie T, et al. Moderate dose-intensive chemotherapy for patients with non-small cell lung cancer: randomised trial, can it improve survival of patients with good performance status?. Oncol Rep. 1999;6:1045–1050
  136. Diehl V, Franklin J, Pfreundschuh M, et al. German Hodgkin’s Lymphoma Study Group Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348:2386–2395
  137. Ardizzoni A, Tjan-Heijnen VC, Postmus PE, et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J Clin Oncol. 2002;20:3947–3955
  138. Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002;112:406–411
  139. Gatzemeier U, Kleisbauer JP, Drings P, et al. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomised study. Am J Clin Oncol. 2000;23:393–400
  140. Hackshaw A, Sweetenham J, Knight A. Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin’s lymphoma?. Br J Cancer. 2004;90:1302–1305
  141. Hidalgo M, Mendiola C, Lopez-Vega JM, et al. A multicenter randomized Phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain. Cancer. 1998;83:719–725
  142. Bohlius J, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev. 2004;3:CD003189
  143. Burton C, Linch D, Hoskin P, et al. A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin’s lymphoma. Br J Cancer. 2006;94:806–813
  144. Balducci L, Tam J, Al-Halawani H, et al. A large study of the older cancer patient in the community setting: Initial report of a randomized controlled trial using pegfilgrastim to reduce neutropenic complications. J Clin Oncol. 2005;23(16s Suppl.):8111
  145. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol. 2004;22:4302–4311
  146. ESMO recommendations for the application of haematopoietic growth factors. Ann Oncol 2005;16(suppl 1):i80–i82.
  147. Campbell C, Bramwell V, Charette M, Oliver T and the Systemic Treatment Disease Site Group. The role of colony-stimulating factor (CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Practice guideline report #12–2 (version 2.2003). Available from: http://www.cancercare.on.ca/pdf/pebc12-2s.pdf.
  148. Cosler LE, Calhoun EA, Agboola O, Lyman GH. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy. 2004;24:488–494
  149. Cosler LE, Sivasubramaniam V, Agboola O, Crawford J, Dale D, Lyman GH. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy. Value Health. 2005;8:47–52
  150. Lyman GH, Kuderer NM. The economics of colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Haematol. 2004;50:129–146
  151. Lyman GH. A predictive model for neutropenia associated with cancer chemotherapy. Pharmacotherapy. 2000;20:11S–104S
  152. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–3051
  153. Vose JM, Crump M, Lazarus H, et al. Randomised, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol. 2003;21:514–519
  154. Grigg A, Solal-Celigny P, Hoskin P, et al. Open-label, randomised study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44:1503–1508
  155. Misset JL, Dieras V, Gruia G, et al. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol. 1999;10:553–560

PII: S0959-8049(06)00391-1

doi: 10.1016/j.ejca.2006.05.002

European Journal of Cancer
Volume 42, Issue 15 , Pages 2433-2453 , October 2006

Article Tools

* Image Usage & Resolution